Persistently high quality of life conferred by coexisting congenital deficiency of terminal complement C9 in a paroxysmal nocturnal hemoglobinuria patient

被引：3

作者：

Hanaoka, Nobuyoshi ^{[1
]}

Murakami, Yoshiko ^{[2
,3
]}

Nagata, Masahide ^{[4
]}

Nagakura, Shoichi ^{[5
]}

Yonemura, Yuji ^{[6
]}

Sonoki, Takashi ^{[1
]}

Kinoshita, Taroh ^{[2
,3
]}

Nakakuma, Hideki ^{[1
]}

机构：

[1] Wakayama Med Univ, Dept Hematol Oncol, Wakayama 6418510, Japan

[2] Osaka Univ, Microbial Dis Res Inst, Osaka, Japan

[3] Osaka Univ, WPI Immunol Frontier Res Ctr, Osaka, Japan

[4] Nagata ENT Clin, Kumamoto, Japan

[5] Natl Hosp Org, Kumamoto Med Ctr, Dept Hematol, Kumamoto, Japan

[6] Kumamoto Univ, Dept Blood Transfus Med & Cell Therapy, Kumamoto, Japan

来源：

BLOOD | 2012年 / 119卷 / 16期

关键词：

ECULIZUMAB; ERYTHROCYTES; EXPRESSION; HEMOLYSIS;

D O I：

10.1182/blood-2012-02-408161

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：3866 / 3868

页数：5

共 10 条

[1] Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases [J].

Fridkis-Hareli, Masha ;

Storek, Michael ;

Mazsaroff, Istvan ;

Risitano, Antonio M. ;

Lundberg, Ante S. ;

Horvath, Christopher J. ;

Holers, V. Michael .

BLOOD, 2011, 118 (17) :4705-4713

[2] Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization [J].

Hill, Anita ;

Rother, Russell P. ;

Arnold, Louise ;

Kelly, Richard ;

Cullen, Matthew J. ;

Richards, Stephen J. ;

Hillmen, Peter .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (04) :567-573

[3] Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria [J].

Hillmen, P ;

Hall, C ;

Marsh, JCW ;

Elebute, M ;

Bombara, MP ;

Petro, BE ;

Cullen, MJ ;

Richards, SJ ;

Rollins, SA ;

Mojcik, CF ;

Rother, RP .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (06) :552-559

[4] Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival [J].

Kelly, Richard J. ;

Hill, Anita ;

Arnold, Louise M. ;

Brooksbank, Gemma L. ;

Richards, Stephen J. ;

Cullen, Matthew ;

Mitchell, Lindsay D. ;

Cohen, Dena R. ;

Gregory, Walter M. ;

Hillmen, Peter .

BLOOD, 2011, 117 (25) :6786-6792

[5] EXPRESSION OF CRYPTANTIGEN TH ON PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA ERYTHROCYTES IN ASSOCIATION WITH A HEMOLYTIC EXACERBATION [J].

NAKAKUMA, H ;

HIDAKA, M ;

NAGAKURA, S ;

NISHIMURA, Y ;

IWAMOTO, N ;

HORIKAWA, K ;

KAWAGUCHI, T ;

KAGIMOTO, T ;

TAKATSUKI, K .

JOURNAL OF CLINICAL INVESTIGATION, 1995, 96 (01) :201-206

[6] ALTERED EXPRESSION OF GANGLIOSIDES IN ERYTHROCYTES OF PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA [J].

NAKAKUMA, H ;

KAWAGUCHI, T ;

HORIKAWA, K ;

HIDAKA, M ;

YONEMURA, Y ;

KAWAKITA, M ;

KAGIMOTO, T ;

IWAMORI, M ;

NAGAI, Y ;

TAKATSUKI, K .

JOURNAL OF CLINICAL INVESTIGATION, 1990, 85 (05) :1456-1461

[7] Eculizumab for paroxysmal nocturnal haemoglobinuria [J].

Parker, Charles .

LANCET, 2009, 373 (9665) :759-767

[8] Hemoglobin normalization after spienectomy in a paroxysmal nocturnal hemoglobinuria patient treated by eculizumab [J].

Risitano, Antonio M. ;

Marando, Ludovica ;

Seneca, Elisa ;

Rotoli, Bruno .

BLOOD, 2008, 112 (02) :449-451

[9] Complement deficiency states and associated infections [J].

Skattum, Lillemor ;

van Deuren, Marcel ;

van der Poll, Tom ;

Truedsson, Lennart .

MOLECULAR IMMUNOLOGY, 2011, 48 (14) :1643-1655

[10] PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA WITH COEXISTING DEFICIENCY OF THE 9TH COMPONENT OF COMPLEMENT - LACK OF MASSIVE HEMOLYTIC ATTACK [J].

YONEMURA, Y ;

KAWAKITA, M ;

KOITO, A ;

KAWAGUCHI, T ;

NAKAKUMA, H ;

KAGIMOTO, T ;

SHICHISHIMA, T ;

TERASAWA, T ;

AKAGAKI, Y ;

INAI, S ;

TAKATSUKI, K .

BRITISH JOURNAL OF HAEMATOLOGY, 1990, 74 (01) :108-113

← 1 →